{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:50:30Z","timestamp":1788403830812,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T00:00:00Z","timestamp":1676246400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fonds De La Recherche Scientifique - FNRS","doi-asserted-by":"publisher","award":["Senior research associate"],"award-info":[{"award-number":["Senior research associate"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The association between graft-versus-host disease (GVHD) occurrence and acute myeloid leukemia (AML) relapse in patients treated with HLA-haploidentical allogeneic hematopoietic stem cell transplantation (Haplo-HCT) with post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis has remained debated. Here, we addressed this issue in patients with active AML at transplantation. 2-year cumulative incidences of relapse and leukemia-free survival (LFS) were 49% and 32.3%, respectively. There were no associations between acute nor chronic GVHD of any grade and lower relapse incidence. However, grade I acute GVHD was associated with better LFS (HR\u2009=\u20090.71, 95% CI 0.51\u20130.99,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.04). In contrast, grade III\u2013IV acute (HR\u2009=\u20093.09, 95% CI 1.87\u20135.12,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.0001) as well as extensive chronic (HR\u2009=\u20093.3, 95% CI 1.81\u20136.04,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0001) GVHD correlated with higher nonrelapse mortality leading to lower LFS (HR\u2009=\u20091.36, 95% CI 0.99\u20131.86,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.056 and HR\u2009=\u20091.97, 95% CI 1.35\u20132.89,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.0004, respectively). In conclusion, these data suggest a dissociation of graft-versus-leukemia effects from GVHD in patients with active AML treated with PTCy-based Haplo-HCT.\n                  <\/jats:p>","DOI":"10.1186\/s13045-023-01403-x","type":"journal-article","created":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T06:03:35Z","timestamp":1676268215000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT"],"prefix":"10.1186","volume":"16","author":[{"given":"Fr\u00e9d\u00e9ric","family":"Baron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Labopin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Tischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Raiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Vydra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Blaise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"St\u00f6lzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Fanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Chevallier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnon","family":"Nagler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Ciceri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,13]]},"reference":[{"key":"1403_CR1","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s13045-021-01159-2","volume":"14","author":"X-H Zhang","year":"2021","unstructured":"Zhang X-H, Chen J, Han M-Z, Huang H, Jiang E-L, Jiang M, et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14:145.","journal-title":"J Hematol Oncol"},{"key":"1403_CR2","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJM198106183042507","volume":"304","author":"PL Weiden","year":"1981","unstructured":"Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N Engl J Med. 1981;304:1529\u201333.","journal-title":"N Engl J Med"},{"key":"1403_CR3","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1182\/blood.V75.3.555.555","volume":"75","author":"MM Horowitz","year":"1990","unstructured":"Horowitz MM, Gale RP, Sondel PM, Goldman JM, Kersey J, Kolb HJ, et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood. 1990;75:555\u201362.","journal-title":"Blood"},{"key":"1403_CR4","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1038\/leu.2012.135","volume":"26","author":"F Baron","year":"2012","unstructured":"Baron F, Labopin M, Niederwieser D, Vigouroux S, Cornelissen JJ, Malm C, et al. Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation. Leukemia. 2012;26:2462\u20138.","journal-title":"Leukemia"},{"key":"1403_CR5","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/nrclinonc.2015.234","volume":"13","author":"CG Kanakry","year":"2016","unstructured":"Kanakry CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13:132.","journal-title":"Nat Rev Clin Oncol"},{"key":"1403_CR6","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-020-00882-6","volume":"13","author":"J Sanz","year":"2020","unstructured":"Sanz J, Galimard J-E, Labopin M, Afanasyev B, Angelucci E, Ciceri F, et al. Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;13:46.","journal-title":"J Hematol Oncol"},{"key":"1403_CR7","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1002\/ajh.26627","volume":"97","author":"F Baron","year":"2022","unstructured":"Baron F, Labopin M, Tischer J, Ciceri F, Raiola AM, Blaise D, et al. Human leukocyte antigen-haploidentical transplantation for relapsed\/refractory acute myeloid leukemia: Better leukemia-free survival with bone marrow than with peripheral blood stem cells in patients \u226555 years of age. Am J Hematol. 2022;97:1065\u201374.","journal-title":"Am J Hematol"},{"key":"1403_CR8","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1182\/blood.2021013054","volume":"139","author":"SR McCurdy","year":"2022","unstructured":"McCurdy SR, Radojcic V, Tsai H-L, Vulic A, Thompson E, Ivcevic S, et al. Signatures of GVHD and relapse after post-transplant cyclophosphamide revealed by immune profiling and machine learning. Blood. 2022;139:608\u201323.","journal-title":"Blood"},{"key":"1403_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13045-022-01287-3","volume":"15","author":"C Zhao","year":"2022","unstructured":"Zhao C, Bartock M, Jia B, Shah N, Claxton DF, Wirk B, et al. Post-transplant cyclophosphamide alters immune signatures and leads to impaired T cell reconstitution in allogeneic hematopoietic stem cell transplant. J Hematol Oncol. 2022;15:64.","journal-title":"J Hematol Oncol"},{"key":"1403_CR10","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/s41409-021-01493-6","volume":"57","author":"A Shimoni","year":"2022","unstructured":"Shimoni A, Labopin M, Angelucci E, Blaise D, Ciceri F, Koc Y, et al. The association of graft-versus-leukemia effect and graft-versus host disease in haploidentical transplantation with post-transplant cyclophosphamide for AML. Bone Marrow Transplant. 2022;57:384\u201390.","journal-title":"Bone Marrow Transplant"},{"key":"1403_CR11","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.bbmt.2017.10.023","volume":"24","author":"SR McCurdy","year":"2018","unstructured":"McCurdy SR, Kanakry CG, Tsai H-L, Kasamon YL, Showel MM, Bola\u00f1os-Meade J, et al. Grade II acute graft-versus-host disease and higher nucleated cell graft dose improve progression-free survival after HLA-haploidentical transplant with post-transplant cyclophosphamide. Biol Blood Marrow Transplant. 2018;24:343\u201352.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1403_CR12","doi-asserted-by":"crossref","unstructured":"Ritacco C, Cem K\u00f6se M, Courtois J, Canti L, Beguin C, Dubois S, et al. Post-transplant cyclophosphamide prevents xenogeneic graft-versus-host disease while depleting proliferating regulatory T cells. iScience. 2023; in press.","DOI":"10.1016\/j.isci.2023.106085"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01403-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01403-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01403-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,13]],"date-time":"2023-02-13T18:15:14Z","timestamp":1676312114000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01403-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,13]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1403"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01403-x","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,13]]},"assertion":[{"value":"5 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific board of the ALWP of the EBMT approved this research project. The study was conducted according to the Declaration of Helsinki, and Good Clinical Practice guidelines. EBMT centres commit to obtain informed consent according to the local regulations applicable at the\u00a0time of transplantation and report pseudonymized data to the EBMT.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"FB has received travel grants and\/or speaker honoraria from Pfizer, Celgene, Abbvie, Novartis and Sanofi. The other authors declare that they have no relevant conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}